Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma Meeting Abstract


Authors: Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; O'Day, S.; Ascierto, P. A.; Testori, A.; Lorigan, P.; Dummer, R.; Sosman, J. A.; Garbe, C.; Lee, R. J.; Nolop, K. B.; Nelson, B.; Hou, J.; Flaherty, K. T.; McArthur, G. A.
Abstract Title: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 18 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-06-20
Language: English
ACCESSION: WOS:000208865800016
PROVIDER: wos
DOI: 10.1200/jco.2011.29.18_suppl.lba4
Notes: Meeting Abstract: LBA4 -- Source: Wos
Altmetric Score
MSK Authors
  1. Paul Chapman
    252 Chapman
Related MSK Work